Related Experiment Video
Updated: May 12, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Treatment with statins and ischemic stroke severity: does the dose matter?
Patricia Martínez-Sánchez1, Blanca Fuentes, Marta Martínez-Martínez
1Department of Neurology and Stroke Center, IdiPAZ Health Research Institute, La Paz University Hospital, Autonomous University of Madrid, Madrid, Spain. patrindalo@hotmail.com
Neurology
|April 19, 2013
Summary
Statin pretreatment, even at lower doses, is linked to reduced ischemic stroke severity. High-dose statins showed a stronger association with milder stroke outcomes in clinical practice.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Ischemic stroke (IS) remains a leading cause of disability.
- Statins are widely used for cardiovascular risk reduction.
- The impact of pre-stroke statin use on IS severity requires further elucidation.
Purpose of the Study:
- To investigate the association between pretreatment with high-dose and low-to-moderate-dose statins and IS severity.
- To analyze these effects within a real-world clinical setting.
Main Methods:
- An observational study of 969 IS patients admitted between 2008-2010.
- Mild stroke severity defined as NIH Stroke Scale (NIHSS) score ≤5.
- Multivariable regression and propensity score matching were employed.
Main Results:
- 27.1% of IS patients were on statins prior to stroke (23% low-moderate dose, 4.1% high-dose).
- Statin use was associated with lower admission NIHSS scores (median 4 for non-users, 4 for low-moderate, 2 for high-dose).
- Pretreatment with statins, particularly high-dose, significantly increased the likelihood of mild stroke severity (ORs ranging from 1.64 to 3.50).
Conclusions:
- Pretreatment with statins is associated with reduced ischemic stroke severity.
- Both high-dose and low-to-moderate-dose statins demonstrate a protective effect on stroke outcomes.
- These findings support the continued use of statins in stroke prevention and management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:21Dose Size and Dosing Frequency: Determination Methods
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...